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ABSTRACT
Background: The effectiveness of pulmonary rehabilita-
tion in advanced COPD is well established, but few data
are available in less advanced disease.
Methods: In a 2 year randomised controlled trial, 199
patients with an average moderate airflow obstruction but
impaired exercise capacity (mean (SD) forced expiratory
volume in 1 s (FEV1) 60 (16)%, peak work load (Wmax)
,70%) were randomised to the INTERdisciplinary
COMmunity-based COPD management programme
(INTERCOM) or usual care. Intervention consisted of
4 months multidisciplinary rehabilitation followed by a 20-
month maintenance phase. Outcomes (4, 12,
24 months): health-related quality of life (St George’s
Respiratory Questionnaire (SGRQ)), exacerbation fre-
quency, MRC dyspnoea score, cycle endurance time
(CET), 6-minute walking distance (6MWD), skeletal
muscle strength and patients’ and caregivers’ perceived
effectiveness.
Results: Between-group comparison after 4 months
revealed the following mean (SE) significant differences in
favour of INTERCOM: SGRQ total score 4.06 (1.39),
p = 0.004; activity and impact subscores, p,0.01; MRC
score 0.33 (0.13), p = 0.01; Wmax 6.0 (2.3) Watt,
p = 0.02; CET 221 (104) s, p = 0.04; 6MWD 13 (6) m,
p = 0.02; hand grip force 4.3 (1.5) lb, p,0.01; and fat-
free mass index 0.34 (0.13) kg/m2, p = 0.01. Between-
group differences over 2 years were as follows: SGRQ
2.60 (1.3), p = 0.04; MRC score 0.21 (0.10), p = 0.048;
CET 253 (104) s, p = 0.0156; 6MWD 18 (8) m,
p = 0.0155. Exacerbation frequency was not different (RR
1.29 (95% CI 0.89 to 1.87)). Patients’ and caregivers’
perceived effectiveness significantly favoured the
INTERCOM programme (p,0.01).
Conclusions: This study shows that a multidisciplinary
community-based disease management programme is
also effective in patients with COPD with exercise
impairment but less advanced airflow obstruction.
Trial registration number: NCT00840892
In patients with advanced chronic obstructive
pulmonary disease (COPD), beneficial effects of
pulmonary rehabilitation programmes on exercise
capacity, dyspnoea and quality of life are well
established.1–3 Limited information is available
about pulmonary rehabilitation in physically
impaired patients with COPD with less advanced
disease stages, although the majority of diagnosed
patients have mild or moderate COPD as defined
by the GOLD guidelines.4–6 Until recently, limited
attention has been given to exercise intolerance
and systemic impairment in patients with earlier
stages of the disease. Patients with COPD are
markedly inactive, and functional exercise capacity
but not forced expiratory volume in 1 s (FEV1)
showed the strongest correlation with physical
activities in daily life.7 A high proportion of patients
with muscle atrophy have mild to moderate COPD,
independent of body mass index.8 9 No difference
was seen in the prevalence of muscle atrophy
between moderate and severe COPD. Commonly
used GOLD stages do not adequately reflect exercise
impairment, systemic impairment and the potential
need for pulmonary rehabilitation. In a previous
paper we showed that impaired exercise capacity was
a significant determinant of disease burden, not only
in patients with severe and very severe COPD but
also in those with moderate disease.10 These findings
provided the rationale to study the efficacy of
pulmonary rehabilitation in patients with COPD
whose exercise capacity is impaired but whose lung
function obstruction is less advanced. To be able to
provide tailored care to these patients close to their
home and to enable access for a large and rapidly
growing population of patients with COPD, we
designed the INTERdisciplinary COMmunity-based
COPD management programme (INTERCOM). The
programme consisted of a 4-month rehabilitation
phase and a 20-month active maintenance phase.
Here we present the results of a 2 year randomised
controlled trial evaluating the efficacy of the
INTERCOM programme compared with usual care.
METHODS
Setting and participants
The INTERCOM trial recruited patients with
COPD who were under the supervision of the
department of respiratory medicine of two general
hospitals in the Netherlands. Patients recruited had
(1) impaired exercise capacity, defined as peak
work load (Wmax) during incremental cycle
ergometry ,70% of the predicted normal value;
(2) GOLD stage 2 or 3 COPD; and (3) were able
and willing to participate in a community-based
programme.11 Patients who had had prior rehabi-
litation and patients with serious co-morbidity
that precluded exercise therapy were excluded.
Patients were judged to be clinically stable at
inclusion by their respiratory physician and phar-
macotherapy was optimised.
Randomisation and interventions
Patients were randomised to the INTERCOM
programme or to usual care using a computerised
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procedure with concealed patient allocation. Outcomes were
assessed at enrolment and 4, 12 and 24 months after the start of
the trial, except for exacerbations which were recorded
continuously and peak exercise capacity which was measured
at baseline and 4 months only. All measurements were assessed
single blind.
INTERCOM programme
The intervention consisted of an intensive 4-month standar-
dised supervised rehabilitation phase and a 20-month active
maintenance phase. The programme was designed to improve
and subsequently maintain exercise capacity, to promote self-
management skills and improve knowledge of COPD.
Nutritional intervention and smoking cessation support were
provided when indicated. The programme was offered by local
physiotherapists and dieticians in the proximity of the patient’s
home and by respiratory nurses from the hospital. Local
caregivers were supervised by colleagues from the hospital.
During the first 4 months the patients visited the phy-
siotherapists twice a week (30 min per visit) for intensive
exercise training consisting of endurance training (cycling and
walking) and four specific exercises for upper and lower
extremities to improve both strength and endurance without
the use of special equipment. Patients were instructed to
perform the same exercises twice a day during 30 min in their
home environment in addition to walking and cycling outside.
Furthermore, all patients participated in an individualised
education programme that was structured using a patient
education book. All smokers were assigned to the respiratory
nurse for standardised smoking cessation counselling according
to the Minimal Intervention Strategy for Lung patients.12
Nutritionally depleted patients received scheduled counselling
(four visits) by a dietician and nutritional supplements
(Respifor, Nutricia, The Netherlands).13
During the 20-month active maintenance phase, patients
visited the physiotherapist once a month to monitor exercise
capacity and adherence to the training and to provide
encouragement to continue the exercise training at home.
After a patient had experienced an exacerbation, he/she was
allowed to start six extra training sessions in 3 weeks at the
physiotherapy practice. Nutritionally depleted patients visited
the dietician four times in the maintenance phase (after 6, 9, 12
and 24 months). The visits to the respiratory nurse were
scheduled upon indication or request.
The usual care group received pharmacotherapy according to
accepted guidelines, a short smoking cessation advice by their
chest physician and, if they were nutritionally depleted, a
recommendation by their respiratory physician to eat more.
Outcomes and follow-up
Primary outcomes were change from baseline in disease-specific
quality of life as assessed by the St George’s Respiratory
Questionnaire (SGRQ) total score and the total number of
exacerbations (moderate plus severe).14 15 A moderate exacerba-
tion was defined as a visit to the general practitioner or
respiratory physician in combination with a prescription of
antibiotics and/or prednisolone or a visit to the emergency
department or day care of a hospital which, according to the
patient, was related to a worsening of COPD symptoms. A
severe exacerbation was defined as hospitalisation for a COPD
exacerbation.
Secondary outcomes were change from baseline in subscores
of the SGRQ (symptom, activity and impact scores), dyspnoea
(modified MRC dyspnoea scale),16 exercise performance
(Wmax), cycle endurance test (CET) at 50% Wmax for maximal
10 min and thereafter at 70% Wmax until exhaustion,13 6-
minute walking test (6MWD), muscle strength (handgrip force
(HGF), isometric quadriceps peak torque (QPT), maximal
inspiratory mouth pressure (Pimax)),17 body composition (fat-
free mass (FFM))18 and lung function. Details of the methods are
provided in the online supplement.
After 24 months, both patients and caregivers were asked for
a global assessment of perceived effectiveness on a 5-point Likert
scale (much improved, slightly improved, no change, slightly
worse and much worse).
Statistical analyses
All reported data analyses were prespecified in the statistical
analyses plan; p values ,0.05 indicated statistical significance.
The analysis was performed according to an intention-to-treat
(ITT) approach. All randomised patients who started the
treatment (in the INTERCOM group) and who completed at
least one post-randomisation outcome measurement (in both
the INTERCOM group and usual care group) were included in
the statistical analysis.
Differences in baseline characteristics between patients who
completed the trial and patients who prematurely discontinued
the trial were statistically tested using independent sample t
tests for continuous normally distributed data, Wilcoxon
Mann-Whitney U tests for continuous non-normally distrib-
uted data and x2 tests for categorical variables.
Repeated measurement analysis was performed to analyse the
change from baseline in all continuous outcome variables using
the SAS procedure PROC MIXED with the covariance among
repeated measures modelled as ‘‘unstructured’’. The model
included treatment, time (ie, measurement at 4, 12 and
24 months), treatment by time interaction, baseline SGRQ
score, smoking status at baseline, FEV1% predicted at baseline
and the self-reported number of exacerbations during the
12 months preceding the trial. Differences in perceived effec-
tiveness were tested using x2 tests. The total number of
exacerbations was compared between treatment groups using
negative binomial regression with treatment, smoking status at
baseline, FEV1% predicted at baseline and the self-reported
number of exacerbations during the 12 months preceding the
trial as factors and the natural logarithm of the length of the
observation period as offset variable. The duration of the
exacerbations was subtracted from the length of the observation
period.
Based on a mean (SD) SGRQ score of 59 (12.5) and an
improvement of 5 units, 98 patients were required in each group
(a= 0.05, b= 0.20).
RESULTS
Patients
Between January 2002 and December 2004, 199 patients were
enrolled in the trial. The patient disposition and the reasons for
drop out are shown in fig 1. The baseline characteristics of the
INTERCOM and usual care groups were comparable (table 1).
At baseline, 39 patients (20%) were nutritionally depleted (23 in
the INTERCOM group and 16 in the usual care group) and
qualified for nutritional intervention. Thirteen of the 199
randomised patients did not start the treatment. The total
drop-out rate was 24.5% (25 patients) in the INTERCOM group
and 16.5% (16 patients) in the usual care group. This difference
was not statistically significant (p = 0.22). In the INTERCOM
Chronic obstructive pulmonary disease
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group drop-outs were older than those who completed the
study, while in the usual care group drop-outs were younger
than those who completed the study.
Outcomes at 4 months
Primary outcomes
Table 2 shows the results of the 4-month intensive part of the
intervention. The SGRQ total score improved in the
INTERCOM group and remained stable in the usual care group
(mean (SE) difference in change from baseline 4.06 (1.39) units
(p = 0.004). The number of exacerbations after 4 months did
not differ between the two groups (RR 1.01 (95% CI 0.57 to
1.79).
Secondary outcomes
The differences between the two groups in mean (SE) change
from baseline in SGRQ activity and SGRQ impact scores were
5.17 (2.00) units (p = 0.01) and 4.26 (1.56) units (p = 0.007),
respectively. The between-group difference in mean (SE) change
from baseline in MRC score was 0.33 (0.13) (p = 0.01). CET
improved by 234 (79) s in the INTERCOM group compared
with 29 (77) s in the usual care group, a mean (SE) difference of
Figure 1 Patient enrolment scheme.
FEV1, forced expiratory volume in 1 s;
Wmax, peak work load.
Chronic obstructive pulmonary disease
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221 (104) s (p = 0.04). Significant differences in favour of the
INTERCOM group were also found for the change from
baseline in Wmax, walking distance, HGF and FFMI, but not
for SGRQ symptom score, QPT, Pimax and BMI (table 2).
Outcomes at 24 months
Primary outcomes
Figure 2A shows the change over time in SGRQ total score. The
SGRQ total score initially improved in the INTERCOM group
and remained stable in the usual care group. At 12 months the
SGRQ score in the INTERCOM group had almost returned to
baseline, whereas in the usual care group it remained stable up
to 12 months and worsened thereafter. Over the total 2-year
period there was a statistically significant difference of 2.60
(1.3) units (p = 0.045) in change from baseline between the two
groups. The 2-year exacerbation frequency was not significantly
different between the groups (RR 1.29; 95% CI 0.89 to 1.87).
Secondary outcomes
Over the 2-year period a significant difference between the
groups in change from baseline MRC dyspnoea score of 0.21
(0.10) units (p = 0.048) was found in favour of the INTERCOM
group (fig 2B). The difference between the INTERCOM group
and the usual care group in exercise capacity increased over
time. Over 2 years, CET significantly increased in the
INTERCOM group by 172 (73) s (p = 0.02) and decreased in
the usual care group by 81 (73) s (p = 0.27), resulting in a mean
(SE) difference of 253 (104) s over the 2-year period which was
statistically significant (p = 0.02, fig 3A). In contrast, functional
exercise capacity reflecting habitual walking speed decreased in
both groups, but significantly less in the INTERCOM group.
The 6MWD score decreased over 24 months in the INTERCOM
group by 15.1 (5.4) m (p,0.01) and in the usual care group by
33.4 (5.2) m (p,0.001), resulting in a mean (SE) difference of
18.3 (7.5) s which was statistically significant (p = 0.016, fig 3B).
Over the total 2-year period, HGF decreased in the usual care
group by 1.9 (0.8) lb (p = 0.02) and in the INTERCOM group by
0.08 (0.8) lb (NS), resulting in a non-significant mean (SE)
difference of 1.8 (1.5) lb (p = 0.12). Over 2 years, Pimax
significantly improved in the INTERCOM group by 0.37
(0.14) kPa (p = 0.008) but did not change in the usual care
group (mean (SE) 0.004 (0.13) kPa). This resulted in a mean (SE)
difference of 0.37 (0.19) kPa over 2 years (p = 0.06). BMI in the
INTERCOM group significantly increased by 0.31 (0.12) kg/m2
Table 1 Baseline characteristics of the randomised study population
Randomised patients (n = 199)
INTERCOM (n = 102) Usual care (n = 97)
Gender (% male) 71% 71%
Age (years) 65.9 (8.8) 67.2 (8.9)
Co-morbidities (n) 1.6 (1.6) 1.5 (1.4)
Exacerbations in 12 months before
trial (n)
1.2 (1.4) 1.0 (1.5)
COPD hospital admissions in
12 months before trial (n)
0.24 (0.52) 0.23 (0.50)
Current smokers (%) 33% 24%
Smoking (pack-years) 38.5 (25.2) 36.1 (26.4)
FEV1 (% predicted) 58 (17) 60 (15)
FEV1/FVC (%) 49 (11) 51 (12)
% patients FEV1 .50% predicted 72% 65%
% patients FEV1 (50% predicted 28% 35%
SGRQ Total score* 39 (15) 38 (15)
SGRQ Activity score 55 (18) 56 (19)
SGRQ Symptom score 45 (19) 41 (22)
SGRQ Impact score 27 (16) 25 (16)
Total MRC score{ 1.7 (1.0) 1.5 (0.9)
6-min walk test (% predicted) 80 (13) 83 (12)
Wmax (% predicted) 60 (19) 61 (17)
HGF (% predicted) 77 (17) 78 (18)
QPT (% predicted) 95 (21) 92 (23)
Fat-free mass (kg/m2) 17.1 (2.0) 17.6 (1.9)
BMI (kg/m2) 26.1 (4.4) 27.3 (4.7)
Data are n (%) or mean (SD).
*St George’s Respiratory Questionnaire: a higher score indicates a worse quality of
life.
{Modified MRC dyspnoea score.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; FFM, fat-free mass; FVC, forced vital capacity; HGF,
handgrip force; 6MWD, 6-minute walking distance; QPT, isometric quadriceps peak
torque; SGRQ, St George’s Respiratory Questionnaire; Wmax, peak exercise capacity.
Table 2 Outcomes of INTERCOM compared with usual care after 4 months
Health outcome
Mean (SE) change from baseline Mean (SE)
difference in change
from baseline as
observed
Adjusted difference
in change from
baseline* p Value
Usual care
(n = 88)
INTERCOM
(n = 87)
SGRQ Total 0.3 (1.0) 23.9 (1.1) 4.2 (1.5) 4.1 (1.4) 0.004
SGRQ Activity 0.9 (1.4) 23.9 (1.5) 4.8 (2.1) 5.2 (2.0) 0.01
SGRQ Symptom 21.4 (1.8) 23.0 (1.9) 1.6 (2.6) 1.1 (2.3) 0.64
SGRQ Impact 0.5 (1.3) 24.1 (1.2) 4.6 (1.8) 4.3 (1.6) ,0.01
MRC dyspnoea score 0.1 (0.1) 20.3 (0.1) 0.4 (0.1) 0.33 (0.13) ,0.01
CET (s) 29 (77) 234 (79) 205 (108) 221 (104) 0.04
6MWD (m) 215.3 (3.9) 21.4 (3.9) 13.8 (5.5) 13.3 (5.6) 0.02
Wmax (W) 20.4 (1.7) 5.2 (1.6) 5.6 (2.3) 6.0 (2.3) 0.01
HGF (lb) 21.2 (1.2) 2.9 (1.1) 4.1 (1.5) 4.3 (1.5) ,0.01
QPT (Nm) 2.4 (2.3) 21.0 (2.2) 3.4 (3.1) 2.1 (3.1) 0.51
Pimax (kPa) 0.06 (0.17) 0.23 (0.16) 0.16 (0.23) 0.27 (0.21) 0.21
FFMI (kg/m2) 20.23 (0.10) 0.15 (0.08) 0.38 (0.13) 0.34 (0.13) 0.01
BMI (kg/m2) 0.02 (0.10) 0.28 (0.1) 0.26 (0.15) 0.23 (0.15) 0.13
FEV1 (% predicted) 21.74 (1.04) 0.87 (0.72) 2.61 (1.27) 2.75 (1.28) 0.03
*Difference in change from baseline adjusted for the baseline value of the parameter, smoking status, FEV1 percentage predicted
and the self-reported number of exacerbations during the 12 months preceding the trial.
BMI, body mass index; CET, cycle endurance test; FEV1, forced expiratory volume in 1 s; FFMI, fat-free mass index; HGF, handgrip
force; 6MWD, 6-minute walking distance; QPT, isometric quadriceps peak torque; Pimax, maximal inspiratory mouth pressure;
SGRQ, St George’s Respiratory Questionnaire; Wmax, peak exercise capacity.
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compared with baseline (p = 0.01). In the usual care group BMI
increased by 0.14 (0.12) kg/m2 (p = 0.24), resulting in a non-
significant mean (SE) difference of 0.18 (0.17) kg/m2 (p = 0.30).
Over the total 24 months the FEV1 in the usual care group
decreased significantly by 2.9 (0.7)% predicted (p,0.001). In the
INTERCOM group the decrease of 1.6 (0.8)% predicted was not
significant. The mean (SE) difference between the two groups
of 1.3 (1.1)% predicted was also not significant. The change
from baseline in SGRQ subscores, QPT and FFMI was not
significantly different between or within the two groups.
Results on perceived effectiveness showed that, both for
patients (fig 4) and respiratory physicians, the perceived
effectiveness was significantly better for the INTERCOM group
with p values of ,0.001 and 0.01, respectively.
DISCUSSION
To the best of our knowledge, this is the first randomised
controlled trial showing that community-based pulmonary
rehabilitation is feasible and effective, even for patients with
less advanced airflow obstruction. The intensive 4-month
rehabilitation resulted in significant improvements in health-
related quality of life, breathlessness, exercise performance,
muscle strength and body composition. In the following
20 months patients participated in an active maintenance
programme. Quality of life, functional exercise capacity and
breathlessness remained significantly different between the
INTERCOM and usual care groups over the entire 2-year
evaluation. The positive results in terms of functional outcomes
were not reflected in a decrease in exacerbation frequency. The
influence of pulmonary rehabilitation on exacerbations and
their appropriateness as a primary outcome variable is still
debated.19 Improved early recognition of exacerbations has been
suggested to explain a similar or even increased exacerbation
frequency after rehabilitation.20 21
Community-based pulmonary rehabilitation programmes for
patients with COPD have been studied before and significant
improvements in exercise capacity, dyspnoea and health-related
quality of life have been reported.22–25 However, mean percen-
tage predicted FEV1 in former studies was substantially lower at
40–45% compared with 60% in our study. Two other Dutch
studies have reported the outcome of community-based
programmes in patients with COPD with comparable airflow
obstruction.20 26 The COPE study evaluated a COPD self-
management programme consisting of fitness, education and
self-treatment of exacerbations and reported no significant
effect on health-related quality of life and 6MWD after 6 and
12 months.20 Campbach et al reported that rehabilitation in
local physiotherapy practices improved exercise tolerance and
quality of life after 6 months, but the study group consisted of
both patients with asthma (35%) and patients with less severe
COPD (65%).26 Most of the community-based programmes
Figure 2 Change from baseline over 24 months in disease-specific
quality of life and dyspnoea. (A) St George’s Respiratory Questionnaire
(SGRQ) total score, p = 0.045. (B) Medical Research Council (MRC)
dyspnoea score, p = 0.048. INTERCOM, INTERdisciplinary COMmunity-
based COPD management programme.
Figure 3 Change from baseline over 24 months in cycle endurance
time (CET) and 6-minute walking distance (6MWD). (A) Cycle endurance
time, p = 0.020. (B) Six-minute walking distance, p = 0.016. Error bars
represent standard errors. p Values are based on repeated measurement
analysis adjusting for baseline St George’s Respiratory Questionnaire
(SGRQ) score, smoking status, percentage predicted forced expiratory
volume in 1 s and self-reported number of exacerbations during the
12 months preceding the trial. INTERCOM, INTERdisciplinary
COMmunity-based COPD management programme.
Chronic obstructive pulmonary disease
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studied previously focused particularly on physical exercise
training without providing a comprehensive multidisciplinary
approach comparable to the INTERCOM programme.22–26
Furthermore, since no data are available on cost-effectiveness
of outpatient or home-based pulmonary rehabilitation in
patients with less severe COPD, we conducted a full economic
evaluation of the INTERCOM programme which is reported
elsewhere.27
The physiotherapy sessions focused on behavioural changes
towards a more physically active lifestyle including walking,
cycling, gardening and any form of physical activity tailored to
the preferences and possibilities for each individual patient.28
This approach has already been proved to be effective in
increasing physical activity in healthy elderly subjects but, at
the time we designed this study in 2001, had not been applied in
COPD before.29 30
The within-group change in CET of 278 s which we observed
over 24 months can be considered as clinically relevant
according to other studies.31 32 Recent guidelines advise using a
submaximal cycle ergometer test instead of peak exercise
capacity as the outcome measure.25 33 While CET significantly
improved after 4 months and was maintained in the active
maintenance phase, no improvement was observed in 6MWD.
This response pattern may indicate that the 6MWD is a less
sensitive outcome measure of pulmonary rehabilitation pro-
grammes, as was indeed recently reported and discussed by
Laviolette et al.31 A remarkable finding was that the 6MWD did
not improve in the INTERCOM group. Rather, it declined
progressively in both groups, although less so in the
INTERCOM group. A potential explanation could be that, in
contrast to most other test protocols, we deliberately chose not
to encourage patients during the walking test but allowed them
to choose their own walking speed. We hypothesise that this
observation is indicative of a progressive decline in physical
activity pattern. Pitta et al recently quantified physical activities
in daily life in healthy control subjects and in patients with
COPD with a wide range in disease severity.34 Patients were
indeed found to have a shorter walking time and lower
movement intensity during walking. Interestingly, and in line
with our hypothesis, walking time assessed by accelerometry
was highly correlated with the 6MWD and more modestly
correlated with maximal exercise capacity, lung function and
muscle force.
In contrast with the improvements in CET, no effect was
seen on quadriceps muscle strength. The lack of effect on this
outcome measure is most likely related to the fact that mean
quadriceps muscle strength at baseline was within normal
limits.
The drop-out rate was 24.5% in the INTERCOM group, only
19% of whom actually started the programme. Considering the
2-year duration of the study, this drop-out rate is not unusual.
Most patients dropped out because they died or because of
serious co-morbidity. It is important to note that only 9% of the
patients in the INTERCOM intervention group dropped out
because of unwillingness to continue their participation. This
low proportion illustrates the feasibility of the community-
based programme. The drop-out rate in the usual care group
was 16.5%. Moreover, while drop-outs in the INTERCOM
group were older than those who completed the study, in the
usual care group drop-outs were younger. To adjust for
potential differences in disease severity between the groups,
the statistical analyses were adjusted for baseline SGRQ score,
smoking status, percentage predicted FEV1 and self-reported
number of exacerbations during the 12 months preceding the
trial.
In conclusion, our interdisciplinary community-based COPD
management programme proved to be a feasible approach to
improve disease-specific quality of life, dyspnoea and functional
exercise capacity during a 2-year follow-up period in patients
with impaired exercise capacity but less advanced airflow
obstruction.
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